Watanabe Y, Iwa T
Cancer. 1984 Jan 15;53(2):248-53. doi: 10.1002/1097-0142(19840115)53:2<248::aid-cncr2820530211>3.0.co;2-g.
A streptococcal preparation, OK-432 was employed as the adjuvant immunotherapeutic agent for lung cancer. To evaluate the clinical efficacy of the OK-432, patients admitted between 1975 and 1979 were randomized into two groups: (1) an immunochemotherapy group and (2) a chemotherapy, or control, group. For evaluation of long-term survival, there were 108 cases in the immunochemotherapy group and 103 cases in the chemotherapy group. When comparing the prognosis of the two groups, the survival rate was statistically higher in the immunochemotherapy group than the control group. The resected cases in Stages I and II showed better prognosis with immunochemotherapy than the cases in the same stages treated with chemotherapy alone. Among the resected cases in the more advanced stages, mostly Stage III and a few cases in the Stage IV, the cases treated with immunochemotherapy also showed more favorable prognosis than the cases treated with chemotherapy alone. In terms of the cell type of the lung cancer, the cases with epidermoid carcinoma in Stages I and II showed significantly better prognosis with immunotherapeutics than the control group. The cases with positive reaction to the streptococcal polysaccharide skin test apparently showed better prognosis than those with negative reaction.
一种链球菌制剂，OK-432被用作肺癌的辅助免疫治疗剂。为评估OK-432的临床疗效，将1975年至1979年入院的患者随机分为两组：（1）免疫化疗组和（2）化疗或对照组。为评估长期生存率，免疫化疗组有108例，化疗组有103例。比较两组的预后时，免疫化疗组的生存率在统计学上高于对照组。I期和II期的切除病例采用免疫化疗的预后比单纯化疗的同阶段病例更好。在更晚期的切除病例中，大多为III期，少数为IV期，采用免疫化疗的病例预后也比单纯化疗的病例更有利。就肺癌的细胞类型而言，I期和II期的表皮样癌病例采用免疫治疗的预后明显优于对照组。对链球菌多糖皮肤试验呈阳性反应的病例预后明显优于阴性反应的病例。
